Discussing AxSpA: Upadacitinib in nr-axSpA and certolizumab pegol by baseline MRI and CRP status
The IMID Forum
00:00
Analysis of Response Rates Based on MRI and CRP Status in nr-axSpA Patients
The chapter delves into the correlation between response rates and MRI and CRP status in nr-axSpA patients, underscoring the significance of evaluating both factors when determining treatment options. Findings reveal that patients with elevated CRP levels exhibit better responses to biologic or targeted synthetic demartic treatment than those with only MRI inflammation.
Transcript
Play full episode
